ASCO‑GU 2026
Quick Data Digest Hub
Short UK expert vlogs and concise summaries to support the management of your mHSPC patients
Welcome to the ASCO‑GU 2026 Quick Data Digest Hub, bringing together key data highlights and insights from the international congress in a format designed for busy UK healthcare professionals. In just a few minutes, you can review data highlights in advanced prostate cancer and consider how they may apply to your own patients.
All content is curated to be practical, concise and applicable to your decision-making in treating advanced prostate cancer patients, including where you may be considering
NUBEQA (darolutamide) for your next suitable patient.
The vlogcasts, PowerPoint presentation and 2-page summaries have been developed and funded by Bayer plc.
Educational Resources
Please refer to the NUBEQA summary of product characteristics before prescribing.
Abbreviations: ASCO‑GU, American Society of Clinical Oncology – Genitourinary Cancers Symposium; mHSPC, metastatic hormone‑sensitive prostate cancer; QoL, quality of life; ARI, androgen receptor inhibitor; ADT, androgen deprivation therapy; MDT, multidisciplinary team.
PP-NUB-GB-2955 | March 2026